1. Home
  2. CLPR vs MDAI Comparison

CLPR vs MDAI Comparison

Compare CLPR & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clipper Realty Inc.

CLPR

Clipper Realty Inc.

HOLD

Current Price

$3.49

Market Cap

54.7M

Sector

Real Estate

ML Signal

HOLD

MDAI

Spectral AI Inc.

HOLD

Current Price

$1.41

Market Cap

47.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPR
MDAI
Founded
2015
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.7M
47.6M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CLPR
MDAI
Price
$3.49
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.25
AVG Volume (30 Days)
78.0K
271.2K
Earning Date
02-13-2026
11-11-2025
Dividend Yield
11.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$154,179,000.00
$23,168,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.90
N/A
52 Week Low
$3.31
$1.04
52 Week High
$5.35
$3.25

Technical Indicators

Market Signals
Indicator
CLPR
MDAI
Relative Strength Index (RSI) 49.81 38.09
Support Level $3.31 $1.41
Resistance Level $3.48 $1.57
Average True Range (ATR) 0.09 0.09
MACD 0.02 -0.00
Stochastic Oscillator 83.33 4.23

Price Performance

Historical Comparison
CLPR
MDAI

About CLPR Clipper Realty Inc.

Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.

About MDAI Spectral AI Inc.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Share on Social Networks: